Impact of late calcineurin inhibitor withdrawal on ambulatory blood pressure and carotid intima media thickness in renal transplant recipients

Transplantation

Volumn 96, Issue 1, 2013, Pages 49-57

  Mourer, Jacqueline S ^a   De Koning, Eelco J P ^a   Van Zwet, Erik W ^a   Mallat, Marko J K ^a   Rabelink, Ton J ^a   De Fijter, Johan W ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Blood pressure; CNI withdrawal; Intima media thickness; Kidney transplantation

Indexed keywords

CALCINEURIN INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HUMAN; HYPERTENSION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SYSTOLIC BLOOD PRESSURE;

ADULT; AGED; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CALCINEURIN; CAROTID INTIMA-MEDIA THICKNESS; CYCLOSPORINE; ENZYME INHIBITORS; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; RISK FACTORS; STEROIDS; SUBSTANCE WITHDRAWAL SYNDROME; TACROLIMUS; TREATMENT OUTCOME;

EID: 84879844494     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3182958552     Document Type: Article

References (63)

1. Howard RJ, Patton PR, Reed AI, et al. The changing causes of graft loss and death after kidney transplantation. Transplantation 2002; 73: 1923.
2. Kasiske BL, Anjum S, Shah R, et al. Hypertension after kidney transplantation. Am J Kidney Dis 2004; 43: 1071.
3. Opelz G, Dohler B. Improved long-term outcomes after renal transplantation associated with blood pressure control. Am J Transplant 2005; 5: 2725.
4. Mancia G, Zanchetti A, Agabiti-Rosei E, et al. Ambulatory blood pressure is superior to clinic blood pressure in predicting treatmentinduced regression of left ventricular hypertrophy. SAMPLE Study Group. Study on Ambulatory Monitoring of Blood Pressure and Lisinopril Evaluation. Circulation 1997; 95: 1464.
5. Staessen JA, Thijs L, Fagard R, et al. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. Systolic Hypertension in Europe Trial Investigators. JAMA 1999; 282: 539.
6. Verdecchia P, Schillaci G, Guerrieri M, et al. Circadian blood pressure changes and left ventricular hypertrophy in essential hypertension. Circulation 1990; 81: 528.
7. Verdecchia P, Schillaci G, Borgioni C, et al. Gender, day-night blood pressure changes, and left ventricular mass in essential hypertension. Dippers and peakers. Am J Hypertens 1995; 8: 193.
8. Lipkin GW, Tucker B, Giles M, et al. Ambulatory blood pressure and left ventricular mass in cyclosporin- and noncyclosporin-treated renal transplant recipients. J Hypertens 1993; 11: 439.
9. Ferreira SR, Moises VA, Tavares A, et al. Cardiovascular effects of successful renal transplantation: a 1-year sequential study of left ventricular morphology and function, and 24-hour blood pressure profile. Transplantation 2002; 74: 1580.
10. O'Leary DH, Polak JF, Kronmal RA, et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 1999; 340: 14.
11. Lorenz MW, Markus HS, Bots ML, et al. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 2007; 115: 459.
12. Bots ML, Hoes AW, Koudstaal PJ, et al. Common carotid intimamedia thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation 1997; 96: 1432.
13. Cofan F, Arias M, Nunez I, et al. Impact of carotid atherosclerosis as assessed by B-mode ultrasonography on the evolution of kidney transplantation. Transplant Proc 2007; 39: 2236.
14. Jardine AG. Assessing the relative risk of cardiovascular disease among renal transplant patients receiving tacrolimus or cyclosporine. Transpl Int 2005; 18: 379.
15. Raisanen-Sokolowski A, Vuoristo P, Myllarniemi M, et al. Mycophenolate mofetil (MMF, RS-61443) inhibits inflammation and smooth muscle cell proliferation in rat aortic allografts. Transpl Immunol 1995; 3: 342.
16. Greenstein SM, Sun S, Calderon TM, et al. Mycophenolate mofetil treatment reduces atherosclerosis in the cholesterol-fed rabbit. J Surg Res 2000; 91: 123.
17. Moore J, Middleton L, Cockwell P, et al. Calcineurin inhibitor sparing with mycophenolate in kidney transplantation: a systematic review and metaanalysis. Transplantation 2009; 87: 591.
18. Mourer JS, Hartigh J, van Zwet EW, et al. Randomized trial comparing late concentration-controlled calcineurin inhibitor or mycophenolate mofetil withdrawal. Transplantation 2012; 93: 887.
19. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461.
20. Ekberg H, Grinyo J, Nashan B, et al. Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study. Am J Transplant 2007; 7: 560.
21. Kuypers DR, Ekberg H, Grinyo J, et al. Mycophenolic acid exposure after administration of mycophenolate mofetil in the presence and absence of cyclosporin in renal transplant recipients. Clin Pharmacokinet 2009; 48: 329.
22. Hazzan M, Labalette M, Copin MC, et al. Predictive factors of acute rejection after early cyclosporine withdrawal in renal transplant recipients who receive mycophenolate mofetil: results from a prospective, randomized trial. J Am Soc Nephrol 2005; 16: 2509.
23. Curtis JJ. Hypertension and kidney transplantation. Curr Opin Nephrol Hypertens 1992; 1: 100.
24. Ventura HO, Malik FS, Mehra MR, et al. Mechanisms of hypertension in cardiac transplantation and the role of cyclosporine. Curr Opin Cardiol 1997; 12: 375.
25. Textor SC, Canzanello VJ, Taler SJ, et al. Cyclosporine-induced hypertension after transplantation. Mayo Clin Proc 1994; 69: 1182.
26. Kurtz A, Della Bruna R, Kuhn K. Cyclosporine A enhances renin secretion and production in isolated juxtaglomerular cells. Kidney Int 1988; 33: 947.
27. Mason J, Muller-Schweinitzer E, Dupont M, et al. Cyclosporine and the renin-angiotensin system. Kidney Int Suppl 1991; 32: S28.
28. Curtis JJ, Luke RG, Jones P, et al. Hypertension in cyclosporine-treated renal transplant recipients is sodium dependent. Am J Med 1988; 85: 134.
29. Mark AL. Cyclosporine, sympathetic activity, and hypertension. N Engl J Med 1990; 323: 748.
30. Margreiter R. Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentre study. Lancet 2002; 359: 741.
31. Kaplan B, Schold JD, Meier-Kriesche HU. Long-term graft survival with neoral and tacrolimus: a paired kidney analysis. J Am Soc Nephrol 2003; 14: 2980.
32. Rowshani AT, Scholten EM, Bemelman F, et al. No difference in degree of interstitial Sirius red-stained area in serial biopsies from area under concentration-over-time curves-guided cyclosporine versus tacrolimustreated renal transplant recipients at one year. J Am Soc Nephrol 2006; 17: 305.
33. Roos-van Groningen MC, Scholten EM, Lelieveld PM, et al.Molecular comparison of calcineurin inhibitor-induced fibrogenic responses in protocol renal transplant biopsies. J Am Soc Nephrol 2006; 17: 881.
34. Parati G, Staessen JA. Hypertension drug trials based on ambulatory blood pressure monitoring: when is a double-blind controlled design needed? J Hypertens 2003; 21: 1237.
35. Jacobi J, Rockstroh J, John S, et al. Prospective analysis of the value of 24-hour ambulatory blood pressure on renal function after kidney transplantation. Transplantation 2000; 70: 819.
36. Paoletti E, Gherzi M, Amidone M, et al. Association of arterial hypertension with renal target organ damage in kidney transplant recipients: the predictive role of ambulatory blood pressure monitoring. Transplantation 2009; 87: 1864.
37. Farmer CK, Goldsmith DJ, Cox J, et al. An investigation of the effect of advancing uraemia, renal replacement therapy and renal transplantation on blood pressure diurnal variability. Nephrol Dial Transplant 1997; 12: 2301.
38. Wadei HM, Amer H, Taler SJ, et al. Diurnal blood pressure changes one year after kidney transplantation: relationship to allograft function, histology, and resistive index. J Am Soc Nephrol 2007; 18: 1607.
39. Covic A, Gusbeth-Tatomir P, Mardare N, et al. Dynamics of the circadian blood pressure profiles after renal transplantation. Transplantation 2005; 80: 1168.
40. van den Dorpel MA, van den Meiracker AH, Lameris TW, et al. Cyclosporin A impairs the nocturnal blood pressure fall in renal transplant recipients. Hypertension 1996; 28: 304.
41. Steigerwalt SP, Brar N, Dhungel A, et al. Improved 24-hour blood pressure control with sirolimus versus calcineurin inhibitor based immunosuppression in renal transplant recipients. Transplant Proc 2009; 41: 4184.
42. Galiatsou E, Morris ST, Jardine AG, et al. Cardiac and vascular abnormalities in renal transplant patients: differential effects of cyclosporin and azathioprine. J Nephrol 2000; 13: 185.
43. Cofan F, Nunez I, Gilabert R, et al. Increased prevalence of carotid and femoral atherosclerosis in renal transplant recipients. Transplant Proc 2001; 33: 1254.
44. Kato A, Takita T, Maruyama Y, et al. Impact of carotid atherosclerosis on long-term mortality in chronic hemodialysis patients. Kidney Int 2003; 64: 1472.
45. Caliskan Y, Oflaz H, Demirturk M, et al. Coronary flow reserve dysfunction in hemodialysis and kidney transplant patients. Clin Transplant 2008; 22: 785.
46. Suwelack B, Witta J, Hausberg M, et al. Studies on structural changes of the carotid arteries and the heart in asymptomatic renal transplant recipients. Nephrol Dial Transplant 1999; 14: 160.
47. Posadzy-Malaczynska A, Kosch M, Hausberg M, et al. Arterial distensibility, intima media thickness and pulse wave velocity after renal transplantation and in dialysis normotensive patients. Int Angiol 2005; 24: 89.
48. Gerhart MK, Seiler S, Grun OS, et al. Indices of systemic atherosclerosis are superior to ultrasound resistance indices for prediction of allograft survival. Nephrol Dial Transplant 2010; 25: 1294.
49. De Lima JJ, Vieira ML, Viviani LF, et al. Long-term impact of renal transplantation on carotid artery properties and on ventricular hypertrophy in end-stage renal failure patients. Nephrol Dial Transplant 2002; 17: 645.
50. Akagun T, Caliskan Y, Alpay N, et al. Long-term prognostic value of coronary flow velocity reserve in renal transplant recipients. Transplant Proc 2011; 43: 2612.
51. Cofan F, Gilabert R, Zambon D, et al. Effect of pravastatin treatment on the evolution of extracoronary atherosclerosis in renal transplant patients. Transplant Proc 2002; 34: 384.
52. Armstrong KA, Hiremagalur B, Haluska BA, et al. Free fatty acids are associated with obesity, insulin resistance, and atherosclerosis in renal transplant recipients. Transplantation 2005; 80: 937.
53. Adamczak M, Blach A, Kolonko A, et al. Plasma adiponectin concentration and left ventricular hypertrophy in kidney transplant patients. Clin Transplant 2011; 25: 561.
54. Su TC, Jeng JS, Chien KL, et al. Hypertension status is the major determinant of carotid atherosclerosis: a community-based study in Taiwan. Stroke 2001; 32: 2265.
55. Su TC, Lee YT, Chou S, et al. Twenty-four-hour ambulatory blood pressure and duration of hypertension as major determinants for intima-media thickness and atherosclerosis of carotid arteries. Atherosclerosis 2006; 184: 151.
56. Shintani Y, Kikuya M, Hara A, et al. Ambulatory blood pressure, blood pressure variability and the prevalence of carotid artery alteration: the Ohasama study. J Hypertens 2007; 25: 1704.
57. Wang JG, Staessen JA, Li Y, et al. Carotid intima-media thickness and antihypertensive treatment: a metaanalysis of randomized controlled trials. Stroke 2006; 37: 1933.
58. Amarenco P, Labreuche J, Lavallee P, et al. Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date metaanalysis. Stroke 2004; 35: 2902.
59. Scholten EM, Cremers SC, Schoemaker RC, et al. AUC-guided dosing of tacrolimus prevents progressive systemic overexposure in renal transplant recipients. Kidney Int 2005; 67: 2440.
60. Cremers SC, Scholten EM, Schoemaker RC, et al. A compartmental pharmacokinetic model of cyclosporin and its predictive performance after Bayesian estimation in kidney and simultaneous pancreaskidney transplant recipients. Nephrol Dial Transplant 2003; 18: 1201.
61. European best practice guidelines for renal transplantation: Section IV. Long-term management of the transplant recipient. IV.5.3. Cardiovascular risks. Hyperlipidaemia. Nephrol Dial Transplant 2002; 17 (Suppl 4): 26.
62. Touboul PJ, Hennerici MG, Meairs S, et al. Mannheim carotid intimamedia thickness consensus (2004-2006). An update on behalf of the Advisory Board of the 3rd and 4thWatching the Risk Symposium, 13th and 15th European Stroke Conferences, Mannheim, Germany, 2004, and Brussels, Belgium, 2006. Cerebrovasc Dis 2007; 23: 75.
63. R Development Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing. 2009.